Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis, a gene editing company listed on Nasdaq under the ticker CLLS, announced its share statistics as of July 31, 2021. The total number of shares in circulation is 45,465,310, while the total voting rights amount to 51,535,159. The company focuses on developing innovative CAR-T immunotherapies for oncology, utilizing their TALEN® gene editing technology and PulseAgile system. Cellectis aims to offer off-the-shelf gene-edited CAR T-cells and is dedicated to treating various cancers through its UCART product candidates.
Cellectis S.A. (NASDAQ: CLLS) will report its Q2 2021 and six-month financial results on August 5, 2021, after US market close. This will be followed by a conference call on August 6, 2021, at 8 AM EDT. Cellectis focuses on gene editing and CAR-T immunotherapies, aiming to develop off-the-shelf therapeutics for cancer. Their UCART products target various cancers and they are advancing their HEAL platform for blood disorders. The company is headquartered in Paris and has operations in New York and Raleigh.
Cellectis S.A. (NASDAQ: CLLS) announced it will release its financial results for Q2 and H1 2021 on August 6, 2021, after U.S. market close. A conference call will follow at 8:00 AM NY time, with dial-in numbers provided. The company specializes in genome editing and developing CAR-T cell therapies for cancer treatment. Cellectis aims to meet unmet medical needs through its innovative products and technologies, including its TALEN® genome editing and PulseAgile electroporation systems. The notice emphasizes Cellectis’ ongoing commitment to advancing therapies for patients.
Cellectis, a pioneering gene editing company, has reported a total of 45,461,310 shares and 51,531,339 voting rights as of June 30, 2021. The company is focused on developing innovative CAR-T immunotherapies for cancer treatment and therapeutic gene editing for various diseases. With over 21 years of expertise, Cellectis utilizes its proprietary technologies to advance hematological malignancies and blood disorders. It operates from its headquarters in Paris and additional locations in New York and Raleigh, with listings on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis announced the development of four new product candidates targeting solid tumors, including UCART20x22, a bi-specific CAR-T cell therapy for B-cell malignancies, and others for mesothelin, MUC1, and cancer-associated fibroblasts. The new .HEAL platform aims to address genetic diseases like Sickle Cell Anemia and lysosomal storage disorders. Additionally, Cellectis is enhancing its GMP manufacturing capabilities to increase production independence and control over gene therapy processes. The company is advancing multiple clinical trials, achieving significant patient enrollment and early positive results.
Cellectis, a clinical-stage biopharmaceutical company, focuses on pioneering allogeneic CAR-T immunotherapies. As of May 31, 2021, the company reported a total of 45,461,310 shares in circulation and 51,531,739 voting rights. Cellectis aims to develop life-saving UCART product candidates for cancers like AML, B-ALL, and MM, leveraging its TALEN® gene editing technology. The company's headquarters are in Paris, with operational sites in New York and Raleigh. Cellectis is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis S.A. held its Annual Shareholders’ General Meeting on June 1, 2021, in Paris, with over 66% of voting rights exercised. Resolutions 1-24 passed, while Resolution 25 was rejected. The detailed voting results can be found on the company's website. Cellectis is pioneering allogeneic CAR-T therapies, focusing on off-the-shelf gene-edited CAR T-cells aimed at treating cancers like acute myeloid leukemia and multiple myeloma. The company is based in Paris, with additional offices in New York and Raleigh, and trades on Nasdaq under the symbol CLLS.
Cellectis S.A. (NASDAQ: CLLS) announced a partnership with Sanofi to supply alemtuzumab, an anti-CD52 monoclonal antibody, for use in Cellectis-sponsored UCART clinical trials. The CD52 knockout technology will allow UCART cells to resist alemtuzumab, enhancing T-cell persistence and expansion. Alemtuzumab will be integrated into lymphodepleting regimens for UCART22 in the BALLI-01 trial and UCART123 in the AMELI-01 trial. The agreement signifies a step toward a commercial supply relationship, aiming to drive progress in cancer therapies.
Cellectis announced key financial metrics as of April 30, 2021, revealing a total of 45,461,310 shares in capital and 51,526,159 voting rights. The company focuses on developing allogeneic CAR-T immunotherapies for cancer treatment, utilizing its proprietary gene editing technology, TALEN®. Cellectis aims to address unmet medical needs in cancers like acute myeloid leukemia and multiple myeloma, backed by over 21 years of expertise. The company is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis S.A. (NASDAQ: CLLS) announced its Q1 2021 financial results, reporting a consolidated net loss of $12 million, or $0.28 per share, compared to a net income of $20 million in Q1 2020. Consolidated revenues decreased to $28 million from $52 million, mainly due to prior upfront payments. The cash position as of March 31, 2021, stood at $231 million, extending its cash runway into 2023. Ongoing clinical trials include BALLI-01 and AMELI-01, with a new collaboration with Cytovia Therapeutics for iPSC-derived NK cells. The company anticipates presenting further clinical data by year-end.